Enquirer Consulting Group

Reachable Buyer Map

Prepared for Marek Buchman · PharmaBlock · August 2026
Here is the map. It covers the US buyer side of outsourced chemistry, process development and active ingredient manufacture: which segments hold the buyers, which seat signs inside each one, and roughly how many companies sit there. Every count on this page was pulled from a public federal register and dated. Where a count does not exist, the page says so instead of estimating one. It describes the market, not your business.
Clinical-stage drug developers
The buyer whose requirement already has a date attached to it. A program in the clinic has material committed to a protocol and a schedule, which is why this segment decides faster than its size suggests. Counted here as companies running at least one open industry-sponsored interventional study with a US site.
Who signs: head or VP of CMC, VP or head of technical operations, director of external manufacturing, and at the smaller companies the chief scientific officer directly.
Roughly 2,800
companies, across 7,731 open industry-sponsored studies with a US site
Commercial pharmaceutical manufacturers
Companies already making and selling drug product, so any decision here is a second-source, capacity or cost decision rather than a first one. Slower to move and harder to enter than anything else on this page. The buying decision also splits in two at this size, and the two halves sit with different people.
Who signs: VP of technical operations, director of external manufacturing, head of CMC on the technical side, and a strategic sourcing lead inside a global external manufacturing group on the commercial side.
1,296
US employers in pharmaceutical and medicine manufacturing; 683 carry 20 or more people, 221 carry 250 or more
Research and discovery-stage companies
The largest segment by company count and the earliest by stage. Chemistry here is often a small internal team, which makes outsourcing the default rather than an exception, and makes the first conversation a technical one rather than a commercial one. One limit worth stating: this code also holds contract research firms and research businesses outside therapeutics, so it is a wider net than drug discovery on its own.
Who signs: head of chemistry, director of discovery or chemical development, chief scientific officer, head of research operations.
4,305
US employers in scientific research and development services; 1,655 carry 20 or more people, 571 carry 100 or more
Firms holding a registered drug establishment
The regulated layer, counted from site registrations rather than from employers, which is why the shape differs from the segments above. Of these firms, 1,944 register a drug manufacturing operation and 429 register an active ingredient manufacturing operation, with only 206 registering both. A registration is a compliance fact and says nothing about revenue or spare capacity, but those counts side by side describe the market more honestly than an estimate would.
Who signs: VP of manufacturing or operations, head of supply chain, quality director, site head.
3,501
US firms, across 5,319 registered establishment sites
Fine and specialty chemical manufacturers
The adjacent buyer most maps of this market leave out entirely. They buy intermediates, building blocks and custom synthesis for their own products, and they buy on specification, purity and lead time rather than on regulatory history. That usually makes them a shorter first conversation than the regulated segments above, and a different one.
Who signs: technical director, VP of research and development, head of sourcing, business development director.
1,411
US employers across basic and other chemical manufacturing; 827 carry 20 or more people, 369 carry 100 or more
Privately funded companies before their first filing
Seed and series A companies often have no benefit plan filing and no registered site, so they are absent from every count above while being among the most active buyers of early chemistry. There is no public register of them. The nearest countable proxy is federal small-business research awards, and that proxy covers all of health research rather than chemistry alone, so treat it as a floor rather than a segment size. This group is reached by name, one company at a time.
Who signs: the founder, the chief scientific officer, the first chemistry hire.
No public register
nearest proxy: 1,328 US organizations held a federal small-business research award in fiscal 2025, across all of health research

Where the openings are

1
The seat that signs moves with the molecule. At discovery it is a chemistry lead. At first-in-human it becomes CMC. At commercial scale it splits, with technical selection sitting in external manufacturing and commercial terms sitting in strategic sourcing. Of the roughly 2,800 clinical-stage companies above, 402 have nothing running past phase 1 today. That is the cohort choosing a supply chain for the first time, and the only one where there is no incumbent to displace.
2
Three counts in one register describe the whole outsourcing market. 1,944 US firms register a drug manufacturing operation. Of those, 1,738 register no active ingredient operation at all. They are making finished product from material somebody else makes. That is not an inference from a market report, it is one file, one day, three filters.
3
The trigger is public, dated and continuous. New study registrations, phase changes, status changes and new site registrations all publish with a date on them. Against 7,731 open studies, something moves most days. Watching several thousand companies for a state change is mechanical work, and it is the one thing a relationship-led channel structurally cannot do, because it hears about the change after the decision.
4
The market is small enough to work by name, and no register holds a person. The three employer segments here sit in mutually exclusive codes and add to 7,012 US employers, 3,165 of them carrying 20 or more people. That is a list one team can work properly inside a year. What none of these registers contain is a name, a seat or a way to reach a human being. Turning 7,012 companies into named people in the right seat is a separate and mechanical job, and it is the part that decides whether any of the above is worth anything.
Built from public federal registers, each pulled on the date shown. Employer counts and workforce bands come from US employers that file a benefit plan, current to the 2024 filing year, deduplicated so one employer counts once. Those bands use plan participants as a headcount proxy, so they indicate scale rather than an exact staff count, and owner-only and very small employers are not published there. Firm and site counts in the regulated segment come from the federal drug establishment register as it stood on 16 August 2026. Clinical program counts come from the federal register of clinical studies on the same date, counting industry-sponsored interventional studies with at least one US location and an open or ongoing status; sponsor names there are free text, so the company figure is rounded after normalizing them, and it includes companies headquartered outside the US that run US sites. The small-business award figure covers federal fiscal 2025. Sector codes are self-reported. The segments come from different registers and overlap, so they are not added together except where the page states the codes are mutually exclusive.
ENQUIRER CONSULTING GROUP
enquirerconsulting.com